
    
      This is an open-label, randomized, parallel group, study of pharmacokinetics, safety,
      tolerance, and efficacy of Posaconazole in the treatment of immunocompromised hosts with
      refractory invasive fungal infections or in subjects who require empiric antifungal therapy.

      The projected number of subjects planned for enrollment is 100 evaluable subjects. The number
      of planned study sites is approximately ten in the United States and approximately eight in
      the rest of the world.
    
  